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107reveal a misunderstanding of the paper because all
the points they raised were already discussed and
clariﬁed in the paper. First, the aim of the study was
to test the hypothesis that nonresponsiveness to
clopidogrel is a modiﬁable risk factor and not
the comparison of prasugrel with clopidogrel, and
ethical issues make unlikely the possibility to perform
a randomized study using clopidogrel in the control
arm in clopidogrel nonresponders. Second, in the
RECLOSE-2 study, as well as in the GRAVITAS
(Gauging Responsiveness with a VerifyNow P2Y12
Assay: Impact on Thrombosis and Safety) trial,
tailored therapy with an increased dose of clopidogrel
in clopidogrel nonresponders had some effect on
in vitro tests, but no clinical beneﬁt (2,3). Thus, the
historical cohort of the RECLOSE-2 trial may be used
as the control arm. Third, the differences in baseline
characteristics between the 2 patients groups were
rigorously considered in the multivariable analyses.
Fourth, the duration of prasugrel treatment, as well
as the major and minor bleeding events, was clearly
reported, with an increase in minor bleeding rate in
prasugrel-treated patients, whereas no difference
between groups was revealed in major bleeding, and
the last ﬁnding supports the safety proﬁle of prasu-
grel in clopidogrel nonresponders. Finally, the
demonstration that high residual platelet reactivity
on clopidogrel is a modiﬁable risk factor puts an
end to what Dr. Bonello and colleagues deﬁne inap-
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After Implantation of a
Balloon-Expandable Aortic
Valve Without Prior Balloon
ValvuloplastyWhen Is Doing Less More?Transcatheter aortic valve replacement (TAVR) is an
established therapeutic option for patients with
severe symptomatic aortic stenosis. However, the
periprocedural stroke rate continues to be relatively
high, ranging between 3% and 5% in randomized
clinical trials and large registries (1,2). Despite the
evolution of the transcatheter valve, delivery system
design, and procedural techniques, stroke rates have
not diminished. Additionally, studies that have uti-
lized diffusion-weighted magnetic resonance imaging
have demonstrated a high rate of silent cerebral
emboli upwards of 70% during TAVR (3). Although
these ﬁndings may reﬂect, to some extent, the nature
of TAVR in a high-risk patient with multiple comor-
bidities, this may also reﬂect a fundamental limita-
tion of the procedure. In fact, transcranial Doppler
studies during TAVR have highlighted the occurrence
of cerebral embolization at virtually all of the time
points during the procedure but seem most frequent
during valve positioning and implantation, suggest-
ing a mechanical interaction between the trans-
catheter valve and the native aortic valve. In
particular, procedural variables suggest that me-
chanical factors such as balloon post-dilation, valve
dislocation or embolization, or the need for a second
valve are associated with a higher cerebrovascular
event rate (4). Additionally, these studies have
identiﬁed the lowest number of transcranial Doppler
events occurring during balloon aortic valvuloplasty
(BAV).
Given these considerations, we read with much
interest the recent paper by Bijuklic et al. (5) in JACC:
Cardiovascular Interventions evaluating the effect of
TAVR without versus with prior BAV on the risk of
cerebral embolization in 87 patients who received a
balloon-expandable valve. Their procedural success
rate was 93.5% with and 98.2% without BAV, and
procedure duration and contrast volume were
signiﬁcantly lower without BAV. The incidence of
new cerebral ischemic lesions in the total cohort was
66.7%. Compared with patients with BAV, those
without BAV had a signiﬁcantly higher total volume
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108of cerebral ischemic lesions (235.4  331.4 mm3 vs.
89.5  128.2 mm3; p ¼ 0.01) (5).
Despite the important ﬁndings of this study,
there are some concerns that would limit the
broader application of this study to a larger patient
population. Despite the overwhelming association
between various procedural variables during the
TAVR procedure, the authors do not detail proce-
dural variables with sufﬁcient granularity to postu-
late a mechanism for their ﬁndings. Speciﬁcally,
they do not mention the number of times the aortic
valve is crossed, duration of the pacing run,
implantation duration, degree of oversizing, number
of inﬂations, need for post-dilation, extent of the
aortic and aortic valve calciﬁcation, and activated
clotting time in the 2 groups. A difference in the
procedural variables may explain the lack of signif-
icant difference between the overall number of new
cerebral ischemic lesions and the signiﬁcant differ-
ence in the volume of cerebral ischemic lesions
between the 2 groups.
Cerebral embolization and stroke will always be a
concern during invasive aortic procedures. Now that
the safety and efﬁcacy of transcatheter valves are
established, optimizing TAVR-related cerebrovascu-
lar outcomes is the next fundamental challenge that
will determine the future role of this technology as
we move to treat a younger and lower-risk patient
subset. For now, is doing less more?*Femi Philip, MD
Garrett B. Wong, MD
Jeffrey A. Southard, MD
*Department of Internal Medicine
Interventional Cardiology, Cardiovascular Medicine
University of California, Davis
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REPLY: Cerebral Embolization AfterImplantation of a Balloon-Expandable Aortic
Valve Without Prior Balloon Valvuloplasty
When Is Doing Less More?We thank Dr. Philip and colleagues for their interest
in our study (1) and appreciate their comments.
In our study comparing transcatheter aortic
valve implantation replacement (TAVR) with versus
without balloon aortic valvuloplasty (BAV) in patients
receiving a balloon-expandable aortic valve, we
found a signiﬁcantly shorter procedural duration and
contrast volume, but a signiﬁcantly higher total vol-
ume of cerebral ischemic lesions in patient without
prior BAV (1).
Dr. Philip and colleagues hypothesized that a dif-
ference in procedural variables, not mentioned in our
paper, may explain the difference in the observed
ﬁndings.
The procedure variables were as follows:
In all patients, the aortic valve was crossed only 1
time, and the prosthesis was implanted using a
routine 2-step slow-inﬂation technique. In the TAVR
group with prior BAV, only 1 balloon inﬂation was
performed.
In all patients, heparin was administered after
insertion of the sheath, and an activated clotting
time >250 s was maintained throughout the
procedure.
In our study, post-dilation, which has been shown
to be a signiﬁcant predictor for stroke in TAVR (1),
was only considered when a paravalvular leak more
than mild was observed. Of 87 patients, 5 required
post-dilation (5.7%): 1 patient in the BAV group (3.1%)
and 4 patients in the group without BAV (7.3%). When
patients with post-dilation were excluded from the
analysis, the difference in the mean volume of
ischemic lesions between the 2 groups remained
statistically signiﬁcant (243.4  334.9 mm3 for 55
patients without BAV and 79.7  117.4 mm3 for
patients with BAV; p ¼ 0.006).
Sizing was performed by transesophageal echo-
cardiography or computed tomography. We therefore
cannot provide data on the degree of oversizing.
However, the use of the 3 available sizes (23, 26, and
29 mm) did not differ between the 2 groups (p ¼ 0.79).
In addition (as shown under Results) the echocardio-
graphic baseline characteristics including mean
